Technical Articles

A once-withdrawn old drug revealed, sixty years later, an entirely new paradigm of targeted protein degradation. This article follows the timeline of how CRBN-DDB1 moved from the thalidomide mystery to center stage of molecular glue therapeutics.

As the substrate receptor of the CRL4 E3 ubiquitin ligase, CRBN relies on DDB1 to bridge the Cullin4-RBX1 core for ubiquitin transfer. This article systematically dissects the complex assembly logic, molecular glue mechanisms and in vitro research es